Compare KeyCorp (KEY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs TG Therapeutics Inc — how do they compare? KeyCorp trades at $22.93 (market cap $24.32B), while TG Therapeutics Inc trades at $49.62 (market cap $7.64B). The key difference: KeyCorp is far larger — about 3.2× TG Therapeutics Inc's market cap, and KeyCorp pays a 3.61% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| KEY | TGTX | |
|---|---|---|
Market Cap | $24.32B | $7.64B |
Sector | Financials | Health |
52-Week High | $23.99 | $59.06 |
52-Week Low | $16.78 | $26.94 |
Dividend Yield | 3.61% | — |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $22.94, up 1.15% today, with a bullish analyst consensus and consistent earnings beats. The stock shows a P/E of 13.27 and net income margin of 26.72%, supported by strong Q2 2026 results. Recent acquisition of Clearwater UK expands its investment banking footprint, while technical indicators signal a bearish trend despite neutral oscillators.
Outlook remains positive with a $29.41 price target, driven by net interest income growth and fee-based expansion. Risks include economic uncertainty impacting loan demand and competitive pressures. The dividend yield of approximately 3.6% adds income appeal, but investors should monitor margin sustainability and macroeconomic headwinds.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
